# Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer

> **NCT06520683** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 180 (estimated)

## Conditions studied

- Colorectal Cancer
- Microsatellite Instability High

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT06520683
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2027-11-01
- **Final completion:** 2030-11-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06520683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06520683, "Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06520683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*